1. Home
  2. Investors
  3. IR-News
2024-Sep-26

MetrioPharm Investor Relations News QIII 2024


Mode of Action of MetrioPharm's Lead Molecule MP1032  ­

Video Presentation by Dr. Brysch

MetrioPharm AG is developing MP1032, a completely novel molecule that is not only extremely safe but can also be used to treat a variety of different diseases. A clinical study in COVID-19 has been successfully completed, and another in the orphan indication Duchenne muscular dystrophy is underway.
 
How can the molecule have such a wide range of efficacy and at the same time cause so few side effects? MetrioPharm has prepared a video presentation with CSO Dr. Wolfgang Brysch that explains how MP1032 works in just four minutes. He explains how MP1032 acts inside macrophages and other cells to regulate the mitochondria, the so-called "power plants of the cell", and to normalize various disease processes at an early stage. Here you can watch this video before it is published on our other channels.
 
If you would like to learn more about the scientific background of MetrioPharm's work and the enormous significance of disrupted mitochondrial signals for the development of inflammatory processes and chronic diseases, you can find open access publications on this topic here and here:

MetrioPharm AG Company Calendar 2024

06.-07. January, Longwood Healthcare Leaders Conference at JPMorgan Healthcare Conference, San Francisco, USA
09. January, Annual Wuxi Global Forum 2024, San Francisco, USA
08.-10. January, Biotech Showcase at JPMorgan Healthcare Conference, San Francisco, USA
10. January, FreeMind's Annual Non-Dilutive Funding Summit, San Francisco, USA
26.-27. February, BIO CEO & Investor Conference, New York, USA
29. February, Sachs Annual European Life Sciences CEO Forum, Zurich, Switzerland
01.-02. March, Duchenne UK 2024 New Horizons Conference, London, UK
03.-06. March, Muscular Dystrophy Association (MDA) Conference, Orlando, USA
18.-20. March, Bio-Europe Spring, Barcelona, Spaain
22.-23. April, Swiss Biotech Day, Basel, Switzerland
24.-25. April, Asia Bio Partnering Forum, Singapur
29.-30. April, LSX World Congress, Biotech, Healthtech, Medtech, London, UK
12.-14. Mai, BioEquity Europe, San Sebastian, Spain
03.-06. June, BIO International Convention, San Diego, USA
27.-30. June, Parents Project Muscular Dystrophy (PPMD) 30th Annual Conference, Orlando, USA
09. July, Biotech Finanz-Gipfel 2024, Berlin, Germany
10.-11. September, ChinaBio Partnering Forum 2024, Shanghai, China
17.-18. September, HealthTech Innovation Days, Paris, France
25.-26. September, 24. Annual Biotech in Europe Forum, Basel, Switzerland
08.-12. October, World Muscle Society Annual Congress, Prag, Czech Republic
29.-31. October, 15. World Congress on Targeting Mitochondria, Berlin, Germany
04.-06. November, BIO-Europe Conference, Stockholm, Sweden
18. November, LSX Investival Showcase Conference, London, UK
19.-21. November, Jefferies 2024 London Healthcare Conference, London, UK

MetrioPharm AG informs 

MetrioPharm uses various channels to inform its shareholders:
In addition to the quarterly newsletter, we also keep you informed about current events in the company with press releases. The press releases can also be found on our website here. If you have not yet been added to our distribution list for press releases, please send us an e-mail at invest@metriopharm.com and we will add you to the distribution list as soon as possible.

You can also network with MetrioPharm via LinkedIn. We use our LinkedIn profile to inform shareholders, experts and business partners about the latest company developments. Please feel free to include us in your LinkedIn community by invitation.

 

Your contact:

MetrioPharm
Investor Relations
T + 41 44 552 7190 
E invest@metriopharm.com
W www.metriopharm.com

  

MetrioPharm AG Download PDF
Download 

next news »